Negative regulation of fibroblast growth factor 10 (FGF-10) by polyoma enhancer activator 3 (PEA3)

European Journal of Cell Biology

Volumn 88, Issue 7, 2009, Pages 371-384

  Chioni, Athina Myrto ^a   Grose, Richard ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Cell migration; FGF 10; PEA3

Indexed keywords

FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2B; TRANSCRIPTION FACTOR PEA3; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL MIGRATION; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; COMPUTER MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; UPREGULATION; WESTERN BLOTTING;

MURINAE;

EID: 65449153305     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2009.01.004     Document Type: Article

References (55)

1. Adnane J., Gaudray P., Dionne C.A., Crumley G., Jaye M., Schlessinger J., Jeanteur P., Birnbaum D., and Theillet C. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 6 (1991) 659-663
2. Baert J.L., Monte D., Musgrove E.A., Albagli O., Sutherland R.L., and de Launoit Y. Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int. J. Cancer 70 (1997) 590-597
3. Barrett J.M., Puglia M.A., Singh G., and Tozer R.G. Expression of Ets-related transcription factors and matrix metalloproteinase genes in human breast cancer cells. Breast Cancer Res. Treat. 72 (2002) 227-232
4. Beer H.D., Florence C., Dammeier J., McGuire L., Werner S., and Duan D.R. Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression. Oncogene 15 (1997) 2211-2218
5. Benz C.C., O'Hagan R.C., Richter B., Scott G.K., Chang C.H., Xiong X., Chew K., Ljung B.M., Edgerton S., Thor A., and Hassell J.A. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15 (1997) 1513-1525
6. Bieche I., Tozlu S., Girault I., Onody P., Driouch K., Vidaud M., and Lidereau R. Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis 25 (2004) 405-411
7. Boukamp P., Petrussevska R.T., Breitkreutz D., Hornung J., Markham A., and Fusenig N.E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106 (1988) 761-771
8. Braun S., auf dem Keller U., Steiling H., and Werner S. Fibroblast growth factors in epithelial repair and cytoprotection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 359 (2004) 753-757
9. Butler J.E., and Kadonaga J.T. The RNA polymerase II core promoter: a key component in the regulation of gene expression. Genes Dev. 16 (2002) 2583-2592
10. Celli G., LaRochelle W.J., Mackem S., Sharp R., and Merlino G. Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J. 17 (1998) 1642-1655
11. Chotteau-Lelievre A., Desbiens X., Pelczar H., Defossez P.A., and de Launoit Y. Differential expression patterns of the PEA3 group transcription factors through murine embryonic development. Oncogene 15 (1997) 937-952
12. Cowden Dahl K.D., Zeineldin R., and Hudson L.G. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol. Cancer Res. 5 (2007) 413-421
13. Davidson B., Goldberg I., Gotlieb W.H., Kopolovic J., Ben-Baruch G., and Reich R. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin. Cancer Res. 9 (2003) 1412-1419
14. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., Teague J., Butler A., Edkins S., Stevens C., Parker A., O'Meara S., Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J., Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M., Leung S.Y., Looijenga L.H., Malkowicz B., Pierotti M.A., The B.T., Yuen S.T., Lakhani S.R., Easton D.F., Weber B.L., Goldstraw P., Nicholson A.G., Wooster R., Stratton M.R., and Futreal P.A. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65 (2005) 7591-7595
15. De Moerlooze L., Spencer-Dene B., Revest J., Hajihosseini M., Rosewell I., and Dickson C. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 127 (2000) 483-492
16. Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D., Thompson D., Ballinger D.G., Struewing J.P., Morrison J., Field H., Luben R., Wareham N., Ahmed S., Healey C.S., Bowman R., SEARCH collaborators, Meyer K.B., Haiman C.A., Kolonel L.K., Henderson B.E., Le Marchand L., Brennan P., Sangrajrang S., Gaborieau V., Odefrey F., Shen C.Y., Wu P.E., Wang H.C., Eccles D., Evans D.G., Peto J., Fletcher O., Johnson N., Seal S., Stratton M.R., Rahman N., Chenevix-Trench G., Bojesen S.E., Nordestgaard B.G., Axelsson C.K., Garcia-Closas M., Brinton L., Chanock S., Lissowska J., Peplonska B., Nevanlinna H., Fagerholm R., Eerola H., Kang D., Yoo K.Y., Noh D.Y., Ahn S.H., Hunter D.J., Hankinson S.E., Cox D.G., Hall P., Wedren S., Liu J., Low Y.L., Bogdanova N., Schürmann P., Dörk T., Tollenaar R.A., Jacobi C.E., Devilee P., Klijn J.G., Sigurdson A.J., Doody M.M., Alexander B.H., Zhang J., Cox A., Brock I.W., MacPherson G., Reed M.W., Couch F.J., Goode E.L., Olson J.E., Meijers-Heijboer H., van den Ouweland A., Uitterlinden A., Rivadeneira F., Milne R.L., Ribas G., Gonzalez-Neira A., Benitez J., Hopper J.L., McCredie M., Southey M., Giles G.G., Schroen C., Justenhoven C., Brauch H., Hamann U., Ko Y.D., Spurdle A.B., Beesley J., Chen X., kConFab, AOCS Management Group, Mannermaa A., Kosma V.M., Kataja V., Hartikainen J., Day N.E., Cox D.R., and Ponder B.A. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 (2007) 1087-1093
17. Feng S., Wang F., Matsubara A., Kan M., and McKeehan W.L. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res. 57 (1997) 5369-5378
18. Fuchs T., and Allgayer H. Transcriptional regulation of the urokinase receptor (u-PAR) - a central molecule of invasion and metastasis. Biol. Chem. 384 (2003) 755-761
19. Grose R., and Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 16 (2005) 179-186
20. Grose R., Fantl V., Werner S., Chioni A.M., Jarosz M., Rudling R., Cross B., Hart I.R., and Dickson C. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 26 (2007) 1268-1278
21. Gross P., and Oelgeschlager T. Core promoter-selective RNA polymerase II transcription. Biochem. Soc. Symp. (2006) 225-236
22. Hiroumi H., Dosaka-Akita H., Yoshida K., Shindoh M., Ohbuchi T., Fujinaga K., and Nishimura M. Expression of E1AF/PEA3, an Ets-related transcription factor in human non-small-cell lung cancers: its relevance in cell motility and invasion. Int. J. Cancer 93 (2001) 786-791
23. Howe L.R., Crawford H.C., Subbaramaiah K., Hassell J.A., Dannenberg A.J., and Brown A.M. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J. Biol. Chem. 276 (2001) 20108-20115
24. Hunter D.J., Kraft P., Jacobs K.B., Cox D.G., Yeager M., Hankinson S.E., Wacholder S., Wang Z., Welch R., Hutchinson A., Wang J., Yu K., Chatterjee N., Orr N., Willett W.C., Colditz G.A., Ziegler R.G., Berg C.D., Buys S.S., McCarty C.A., Feigelson H.S., Calle E.E., Thun M.J., Hayes R.B., Tucker M., Gerhard D.S., Fraumeni Jr. J.F., Hoover R.N., Thomas G., and Chanock S.J. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39 (2007) 870-874
25. Ibrahimi O.A., Zhang F., Eliseenkova A.V., Itoh N., Linhardt R.J., and Mohammadi M. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum. Mol. Genet. 13 (2004) 2313-2324
26. Iwasaki M., Nishikawa A., Akutagawa N., Fujimoto T., Teramoto M., Sakaguchi Y., Kato H., Ito M., Yoshida K., and Kudo R. E1AF/PEA3 reduces the invasiveness of SiHa cervical cancer cells by activating serine proteinase inhibitor squamous cell carcinoma antigen. Exp. Cell Res. 299 (2004) 525-532
27. Jang J.H., Shin K.H., and Park J.G. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 61 (2001) 3541-3543
28. Jat P.S., Noble M.D., Ataliotis P., Tanaka Y., Yannoutsos N., Larsen L., and Kioussis D. Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc. Natl. Acad. Sci. USA 88 (1991) 5096-5100
29. Katoh M. Cancer genomics and genetics of FGFR2. Int. J. Oncol. 33 (2008) 233-237
30. Katoh Y., and Katoh M. Comparative genomics on FGF7, FGF10, FGF22 orthologs, and identification of fgf25. Int. J. Mol. Med. 16 (2005) 767-770
31. Kobberup S., Nyeng P., Juhl K., Hutton J., and Jensen J. ETS-family genes in pancreatic development. Dev. Dyn. 236 (2007) 3100-3110
32. Kurban G., Ishiwata T., Kudo M., Yokoyama M., Sugisaki Y., and Naito Z. Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. Oncol. Rep. 11 (2004) 987-991
33. Liu Y., Jiang H., Crawford H.C., and Hogan B.L. Role for ETS domain transcription factors Pea3/Erm in mouse lung development. Dev. Biol. 261 (2003) 10-24
34. Liu Y., Borchert G.L., and Phang J.M. Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells. J. Biol. Chem. 279 (2004) 18694-18700
35. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ddCt method. Methods 25 (2001) 402-408
36. Matsuike A., Ishiwata T., Watanabe M., and Asano G. Expression of fibroblast growth factor (FGF)-10 in human colorectal adenocarcinoma cells. J. Nippon Med. Sch. 68 (2001) 397-404
37. Memarzadeh S., Xin L., Mulholland D.J., Mansukhani A., Wu H., Teitell M.A., and Witte O.N. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12 (2007) 572-585
38. Meyer K.B., Maia A.T., O'Reilly M., Teschendorff A.E., Chin S.F., Caldas C., and Ponder B.A. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 6 (2008) e108
39. Min H., Danilenko D.M., Scully S.A., Bolon B., Ring B.D., Tarpley J.E., DeRose M., and Simonet W.S. Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev. 12 (1998) 3156-3161
40. Myers E., Hill A.D., Kelly G., McDermott E.W., O'Higgins N.J., and Young L.S. A positive role for PEA3 in HER2-mediated breast tumour progression. Br. J. Cancer 95 (2006) 1404-1409
41. Nomura S., Yoshitomi H., Takano S., Shida T., Kobayashi S., Ohtsuka M., Kimura F., Shimizu H., Yoshidome H., Kato A., and Miyazaki M. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br. J. Cancer 99 (2008) 305-313
42. Ornitz D.M., and Itoh N. Fibroblast growth factors. Genome Biol. 2 (2001) REVIEWS3005
43. Pollock P.M., Gartside M.G., Dejeza L.C., Powell M.A., Mallon M.A., Davies H., Mohammadi M., Futreal P.A., Stratton M.R., Trent J.M., and Goodfellow P.J. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26 (2007) 7158-7162
44. Ricol D., Cappellen D., El Marjou A., Gil-Diez-de-Medina S., Girault J.M., Yoshida T., Ferry G., Tucker G., Poupon M.F., Chopin D., Thiery J.P., and Radvanyi F. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 18 (1999) 7234-7243
45. Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nurnberg G., Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., Li Y., Becker C., Lehnerdt K., Cremers C.W., Yüksel-Apak M., Nürnberg P., Kubisch C., Schlessinger J., van Bokhoven H., and Wollnik B. Mutations in different components of FGF signaling in LADD syndrome. Nat. Genet. 38 (2006) 414-417
46. Schug J. Using TESS to predict transcription factor binding sites in DNA sequences. Curr. Protoc. Bioinform. 21 (2003) 2.6.1-2.6.15
47. Sekine K., Ohuchi H., Fujiwara M., Yamasaki M., Yoshizawa T., Sato T., Yagishita N., Matsui D., Koga Y., Itoh N., and Kato S. Fgf10 is essential for limb and lung formation. Nat. Genet. 21 (1999) 138-141
48. Shams I., Rohmann E., Eswarakumar V.P., Lew E.D., Yuzawa S., Wollnik B., Schlessinger J., and Lax I. Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway. Mol. Cell. Biol. 27 (2007) 6903-6912
49. Sharrocks A.D. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2 (2001) 827-837
50. Theodorou V., Boer M., Weigelt B., Jonkers J., van der Valk M., and Hilkens J. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 23 (2004) 6047-6055
51. Wilkie A.O., Patey S.J., Kan S.H., van den Ouweland A.M., and Hamel B.C. FGFs, their receptors, and human limb malformations: clinical and molecular correlations. Am. J. Med. Genet. 112 (2002) 266-278
52. Xing X., Wang S.C., Xia W., Zou Y., Shao R., Kwong K.Y., Yu Z., Zhang S., Miller S., Huang L., et al. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat. Med. 6 (2000) 189-195
53. Yu Z., Xia W., Wang H.Y., Wang S.C., Pan Y., Kwong K.Y., Hortobagyi G.N., and Hung M.C. Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Mol. Carcinog. 45 (2006) 667-675
54. Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., and Ornitz D.M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281 (2006) 15694-15700
55. Zhang Y., Wang H., Toratani S., Sato J.D., Kan M., McKeehan W.L., and Okamoto T. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc. Natl. Acad. Sci. USA 98 (2001) 11336-11340